INTRODUCTION
Sarcoma is a heterogeneous malignancy of connective tissue. There are more than 50 subtypes, each with distinct clinical and biologic features. Leiomyosarcoma (LMS) arises from smooth muscle, most often in the uterus or retroperitoneum. Localized disease is treated surgically; unfortunately, relapse occurs in 40% to 70% of patients. 1, 2 Advanced LMS is treated with chemotherapy. The most active regimens, doxorubicin and olaratumab or gemcitabine and docetaxel, are associated with response rates of 15% to 35% and progression-free survival of 4 to 7 months. [3] [4] [5] [6] The cytotoxic agent trabectedin and the tyrosine kinase inhibitor pazopanib are used after chemotherapy. 7, 8 Clinical trials with immune checkpoint blockade have been disappointing, possibly owing to a tumor microenvironment populated by immunosuppressive macrophages. 9, 10 The alkylating agent dacarbazine (DTIC), one of the oldest chemotherapeutics used in sarcoma, is often used as a therapy of last resort, but it has durable activity in some patients with LMS. Here, we describe a case of LMS with homozygous deletion of breast cancer type 2 (BRCA2) susceptibility protein and an exceptional response to dacarbazine. We also discuss the implications of this alteration for the DNA damage response to alkylating agents and review emerging data, which suggest that LMS harbors characteristic defects in the homologous recombination (HR) DNA damage response pathway.
CASE SUMMARY
A 51-year-old woman presented to her family physician in December 2008 with abdominal distension. Contrast-enhanced computed tomography revealed a 40-cm pelvic mass. She underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, appendectomy, and debulking. Pathology revealed high-grade LMS of the uterus metastatic to the neoappendix and bowel wall. Chest imaging was unremarkable. She received six cycles of adjuvant gemcitabine and docetaxel and entered surveillance. Disease was deemed unresectable. She was enrolled in a randomized phase III study that evaluated trabectedin versus DTIC in sarcoma. She began treatment with DTIC in April 2013. Study-related computed tomography scans every 3 months demonstrated incremental regression, and by February 2014, she had no radiographic evidence of malignancy (Fig 1) and has continued to receive DTIC. Genomic sequencing of the November 2012 tumor revealed homozygous deletion of BRCA2, several variants of unknown significance, copy number gain of cyclin E1, epidermal growth factor receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor alpha, and copy number loss of phosphate and tensin homolog (PTEN). The next-generation sequencing platform used did not evaluate for germ line mutations. The tumor showed no evidence of O 6 -methylguanine (O 6 -MeG) DNA methyltransferase (MGMT) promoter methylation or mismatch repair deficiency.
In

DISCUSSION
DTIC, an alkylating agent, was among the first chemotherapies used for sarcoma and has served as the comparator for randomized trials of novel drugs. DTIC and its oral counterpart temozolomide (TMZ) are metabolized to a highly reactive methyldiazonium cation which methylates DNA at several sites, including O 6 -MeG. The O 6 -MeG lesion is responsible for the cytotoxicity of both agents; therefore, both DTIC and TMZ are considered O 6 alkylating agents. O 6 -MeG is efficiently repaired by the MGMT enzyme, which removes the methyl adduct from O 6 -guanine, restoring the normal guanine base.
11 O 6 alkylating agents are most effective in cancers with low MGMT expression, such as melanoma and glioblastoma, in which O 6 -MeG cannot be efficiently repaired. Approximately 40% of glioblastoma patients harbor MGMT promoter methylation, and these patients derive greatest benefit from TMZ. [12] [13] [14] The normal cellular response to O 6 -MeG highlights several distinct but interrelated signaling pathways that make up the DNA damage response. Different types of damage, whether inflicted by environmental insults or chemotherapy, provoke specific repair mechanisms. 15 The initial response to O 6 -MeG requires MGMT (Fig 2) . If left unrepaired, the O 6 -MeG base improperly pairs with thymidine during DNA replication. These mismatched bases are recognized by another DNA damage repair pathway, mismatch repair, which excises the newly synthesized strand while leaving the defective template behind, resulting in futile cycles of mismatch repair and eventually leading to replication fork arrest with induction of DNA single-and double-stranded breaks (DSBs). 16 DSBs represent the most cytotoxic form of DNA damage, and O 6 -MeG-induced DSBs are the apoptosis-triggering lesion responsible for cell death from TMZ and DTIC. 17 Cells deficient in mismatch repair enzymes are tolerant to mismatched base pairs, do not accumulate cytotoxic DSBs, and are relatively resistant to TMZ and DTIC.
Repair of highly cytotoxic DSBs is essential for cell survival and occurs through the nonhomologous end-joining or HR DNA damage response pathways. Nonhomologous end-joining is a low-fidelity repair mechanism that joins broken strands without referencing a template, thus inducing mutations and genomic instability. HR is the preferred mechanism for DSB repair and uses a template strand to restore damaged DNA to the original sequence. BRCA2 plays an essential role in HR by recruiting another protein, RAD51, to sites of DNA damage and facilitating strand invasion and initiation of HR. Tumors with loss of BRCA2 are defective in HR and highly sensitive to DSB-inducing agents such as platinum chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors. 18 The anticancer efficacy of O 6 alkylating agents such as DTIC and TMZ was traditionally felt to depend on the status of the MGMT and mismatch repair pathway; cells with deficient MGMT and intact mismatch repair should accumulate DSBs and demonstrate sensitivity to these drugs. However, a critical role for HR has been highlighted in recent preclinical studies primarily in glioblastoma models, in which TMZ is the standard of care. 19 Here, disruption of the HR pathway profoundly potentiated the antitumor activity of TMZ. [20] [21] [22] Furthermore, resistance to TMZ and DTIC was not mediated by re-expression of MGMT or acquired mismatch repair deficiency but by adaptive tumor cell augmentation of HR repair. 16, 23, 24 Recently, a model capturing the combined status of multiple repair pathways was found to be much more effective in predicting cytotoxicity from O 6 alkylating agents than assessing MGMT alone, and HR pathway status was of major import. 25 Because the HR pathway ultimately determines whether TMZ-and DTIC-induced DSBs are repaired, defective HR, such as that induced by BRCA2 loss, may sensitize patients to treatment with these drugs and warrants further evaluation as a predictive biomarker. The failure to observe MGMT promoter methylation in this case (confirmed on repeat testing) is curious because intact MGMT might be expected to repair the upstream O -methylguanine improperly pairs with a thymidine base during DNA replication. The mismatch repair pathway normally attempts to repair this mismatch but is unable to effectively do so, and multiple futile repair attempts ultimately induce a double-stranded DNA break (DSB). DSBs are the most cytotoxic form of DNA damage and are repaired by several pathways. The homologous recombination (HR) pathway is the preferred response to DSBs because HR uses a template strand to return DNA to the original sequence, whereas other pathways are less conservative and lead to accumulation of mutations, genomic instability, and cell death. In this model, cells with low MGMT activity, intact mismatch repair, and defective HR would be predicted to be most sensitive to O 6 alkylating agents and the DNA damage they induce.
activity. 25 Aside from epigenetic modification, other mechanisms of MGMT inactivation occur such as mutation and phosphorylation. 26 Second, in the setting of marked HR dysfunction imparted by BRCA2 loss, only a small population of O 6 -MeG-induced DSBs may be sufficient for cytotoxicity. Our findings suggest that dysfunctional HR alone may be sufficient to sensitize tumors to alkylating agents in certain contexts.
Emerging -omics studies suggest that LMS frequently harbors defects in HR, of which our patient's BRCA2 loss is emblematic. In a wholeexome and transcriptomic sequencing study of 49 LMS tumors, mutations in TP53 (49%), retinoblastoma (27%), and ATRX (24%) were most common but are not actionable. 27 Moreover, the tumor mutational burden was low, suggesting that immune checkpoint inhibitors are of limited benefit. Interestingly, deleterious alterations in HR pathway genes were observed in most LMS tumors and included PTEN (57%), BRCA2 (53%), FANCA (27%), ATM (22%), CHEK1 (22%), XRCC3 (18%), CHEK2 (12%), BRCA1 (10%), and RAD51 (10%). An Alexandrov-Catalogue of Somatic Mutations in Cancer (COSMIC) signature for defective HR contributed to the mutational signature in 98% of LMS tumors. 27 A separate analysis of 80 patients with LMS that used The Cancer Genome Atlas revealed different gene expression signatures between soft tissue and uterine LMS, with the latter harboring a higher DNA damage response score. 28 Unfortunately, the frequency of germ line alterations in HR genes among patients with LMS remains uncertain. In a comprehensive molecular study of 500 patients with various solid tumors, pathogenic germ line mutations were found in 12%, and 75% of these were in DNA repair genes, highlighting the importance of the germ line analysis, which is often not performed in clinical next-generation sequencing assays. 29 A defective HR phenotype is of therapeutic relevance. Several approaches to targeting cancerrelated vulnerabilities in HR -deficient tumors are being explored. 15 Several of these approaches incorporate PARP inhibitors, a novel class of DNA-damaging anticancer therapeutics. Preclinical studies of the PARP inhibitor olaparib with TMZ showed promise in LMS. 30 Although there are concerns regarding the tolerability of such combinations, therapeutic approaches exploiting HR deficiency are worthy of further study in LMS, an aggressive sarcoma subtype with poor outcomes with existing treatments.
